- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) partners with Alco Prevention Canada for non-exclusive North American distribution of BreathLogix.
- The BreathLogix device uses patent-pending technology to autonomously perform alcohol screenings, reducing costs and maintenance time.
- BreathLogix is being effectively utilized in Montana's 24/7 Sobriety Program, showcasing substantial cost and time savings.
Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) has entered into a non-exclusive distribution agreement with Alco Prevention Canada, a Montreal-based company with 4,000 points of sale and 45 agents globally, to distribute its BreathLogix autonomous alcohol breathalyzer devices across North America. The agreement aims to enhance the market reach of BreathLogix, leveraging Alco Prevention's extensive distribution capabilities.
The BreathLogix device features innovative patent-pending pre-calibrated cartridge technology, which eliminates the need for costly calibration equipment and technician site visits. The autonomous system performs alcohol screenings, captures user photos for identity verification, and delivers real-time Blood Alcohol Content (BAC) results through automated reporting via text, email, and a web portal.
Currently in use at the Friedel Clinic in Montana as part of the 24/7 Sobriety Program, the BreathLogix device is delivering significant cost and time efficiencies by negating the requirement for dedicated in-house screening administrators typically necessary for such programs. The device's implementation highlights its potential for broader adoption in various industry settings.
The company, Cannabix Technologies, is also in talks with additional distributors, aiming to expand its market presence beyond North America.
